Acumen Pharmaceuticals, Inc. (ABOS): Price and Financial Metrics

Acumen Pharmaceuticals, Inc. (ABOS): $3.56

0.08 (+2.30%)

POWR Rating

Component Grades













Add ABOS to Watchlist
Sign Up

Industry: Biotech



in industry

ABOS Stock Price Chart Interactive Chart >

Price chart for ABOS

ABOS Price/Volume Stats

Current price $3.56 52-week high $26.98
Prev. close $3.48 52-week low $3.02
Day low $3.38 Volume 77,500
Day high $3.61 Avg. volume 233,651
50-day MA $4.03 Dividend yield N/A
200-day MA $8.74 Market Cap 144.18M

Acumen Pharmaceuticals, Inc. (ABOS) Company Bio

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.

ABOS Latest News Stream

Event/Time News Detail
Loading, please wait...

ABOS Latest Social Stream

Loading social stream, please wait...

View Full ABOS Social Stream

Latest ABOS News From Around the Web

Below are the latest news stories about Acumen Pharmaceuticals Inc that investors may wish to consider to help them evaluate ABOS as an investment opportunity.

Bullish Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insiders filled their treasuries with US$5.7m worth of stock over last year

Multiple insiders secured a larger position in Acumen Pharmaceuticals, Inc. ( NASDAQ:ABOS ) shares over the last 12...

Yahoo | December 30, 2021

Comparing Acumen Pharmaceuticals (NASDAQ:ABOS) and Adverum Biotechnologies (NASDAQ:ADVM)

Adverum Biotechnologies (NASDAQ:ADVM) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Adverum Biotechnologies and Acumen Pharmaceuticals revenue, earnings per share []

Transcript Daily | December 24, 2021

Acumen Pharmaceuticals (NASDAQ:ABOS) Lowered to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Acumen Pharmaceuticals (NASDAQ:ABOS) from a hold rating to a sell rating in a research note released on Tuesday morning, reports. According to Zacks, Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The companys product pipeline consist ACU193. Acumen Pharmaceuticals []

Transcript Daily | November 26, 2021

Ocugen (NASDAQ:OCGN) versus Acumen Pharmaceuticals (NASDAQ:ABOS) Critical Contrast

Ocugen (NASDAQ:OCGN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Analyst Ratings This is a summary of current recommendations and price targets for Ocugen and Acumen […]

Transcript Daily | November 25, 2021

15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital

In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […]

Yahoo | November 25, 2021

Read More 'ABOS' Stories Here

ABOS Price Returns

1-mo -7.77%
3-mo -39.25%
6-mo -54.94%
1-year N/A
3-year N/A
5-year N/A
YTD -47.34%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5809 seconds.